A Score for Risk of Thrombolysis-Associated Hemorrhage Including Pretreatment
with Statins by Erdur, Hebun et al.
February 2018 | Volume 9 | Article 741
Original research
published: 16 February 2018
doi: 10.3389/fneur.2018.00074
Frontiers in Neurology | www.frontiersin.org
Edited by: 
Ashfaq Shuaib, 
University of Alberta, Canada
Reviewed by: 
Marco Pasi, 
Massachusetts General Hospital, 
United States  
W. Taylor Kimberly, 
Massachusetts General Hospital, 
United States
*Correspondence:
Hebun Erdur  
hebun.erdur@charite.de
Specialty section: 
This article was submitted to 






Erdur H, Polymeris A, Grittner U, 
Scheitz JF, Tütüncü S, Seiffge DJ, 
Audebert HJ, Nolte CH, Engelter ST 
and Rocco A (2018) A Score for Risk 
of Thrombolysis-Associated 
Hemorrhage Including Pretreatment 
with Statins. 
Front. Neurol. 9:74. 
doi: 10.3389/fneur.2018.00074




Hebun Erdur1,2*, Alexandros Polymeris3, Ulrike Grittner4,5, Jan F. Scheitz1,4,6,  
Serdar Tütüncü1,4, David J. Seiffge3, Heinrich J. Audebert1,4, Christian H. Nolte1,4,  
Stefan T. Engelter3,7 and Andrea Rocco1,4
1 Department of Neurology, Charité—Universitätsmedizin Berlin, Berlin, Germany, 2 Berlin Institute of Health, Berlin, Germany, 
3 Department of Neurology and Stroke Center, University of Basel, University Hospital Basel, Basel, Switzerland, 4 Center for 
Stroke Research, Charité—Universitätsmedizin Berlin, Berlin, Germany, 5 Department for Biostatistics and Clinical 
Epidemiology, Charité—Universitätsmedizin Berlin, Berlin, Germany, 6 NeuroCure, Cluster of Excellence, Charité—
Universitätsmedizin Berlin, Berlin, Germany, 7 Neurorehabilitation Unit, University of Basel, University Center for Medicine of 
Aging and Rehabilitation, Felix Platter Hospital, Basel, Switzerland
Background: Symptomatic intracranial hemorrhage (sICH) after intravenous thrombo­
lysis with recombinant tissue­plasminogen activator (rt­PA) for acute ischemic stroke 
is associated with a poor functional outcome. We aimed to develop a score assessing 
risk of sICH including novel putative predictors—namely, pretreatment with statins and 
severe renal impairment.
Methods: We analyzed our local cohort (Berlin) of patients receiving rt­PA for 
acute ischemic stroke between 2006 and 2016. Outcome was sICH according to 
ECASS­III criteria. A multiple regression model identified variables associated with sICH 
and receiver operating characteristics were calculated for the best discriminatory model 
for sICH. The model was validated in an independent thrombolysis cohort (Basel).
results: sICH occurred in 53 (4.0%) of 1,336 patients in the derivation cohort. Age, 
baseline National Institutes of Health Stroke Scale, systolic blood pressure on admission, 
blood glucose on admission, and prior medication with medium­ or high­dose statins 
were associated with sICH and included into the risk of intracranial hemorrhage score. 
The validation cohort included 983 patients of whom 33 (3.4%) had a sICH. c­Statis­
tics for sICH was 0.72 (95% CI 0.66–0.79) in the derivation cohort and 0.69 (95% CI 
0.60–0.77) in the independent validation cohort. Inclusion of severe renal impairment did 
not improve the score.
conclusion: We developed a simple score with fair discriminating capability to predict 
rt­PA­related sICH by adding prior statin use to known prognostic factors of sICH. This 
score may help clinicians to identify patients with higher risk of sICH requiring intensive 
monitoring.
Keywords: ischemic stroke, thrombolysis, hemorrhage, stroke outcome, predictive models
inTrODUcTiOn
Symptomatic intracranial hemorrhage (sICH) occurs in 2–4% of patients receiving intravenous 
recombinant tissue-plasminogen activator (rt-PA) for acute ischemic stroke (1–3). sICH is associ-
ated with poor clinical outcome and a high fatality rate of approximately 50% (4).
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Therefore, the accurate identification of patients with higher 
risk of rt-PA-related hemorrhage is of high relevance. Several 
predictive instruments for estimated risk of sICH after thrombo-
lytic therapy have been developed in recent years (e.g., HAT, MSS, 
THRIVE, SITS-sICH, SEDAN, and TURN) (5–10). However, 
they showed modest to moderate discriminatory ability only and 
it has been suggested that the accuracy of scores may be improved 
by inclusion of additional risk factors (11). Indeed, novel putative 
risk factors for sICH have been identified, namely, severe renal 
impairment and prior use of medium to high-dose statins (12, 13), 
which are not part of existing sICH scores. Furthermore, some of 
the existing scores rely on identification of early ischemic changes 
on computer tomography (CT), requiring trained stroke neurolo-
gists or neuroradiologists (14). Moreover, scores including early 
ischemic changes on CT are not applicable in MRI-based throm-
bolysis. We therefore aimed to develop a simple score based on 
history, clinical, and laboratory data, which may be used in clini-
cal settings without quick and reliable assessment of early signs 
of infarction on CT. Specifically, we aimed to evaluate whether 
inclusion of severe renal impairment and prior use of statins can 
improve the discrimination of sICH in a predictive score.
MaTerials anD MeThODs
study Population and Data acquisition
From January 2006 to March 2016, all consecutive patients 
with acute ischemic stroke admitted to our tertiary care center 
(Department of Neurology, Charité—Universitätsmedizin 
Berlin, Campus Benjamin Franklin) and undergoing intrave-
nous thrombolysis were included in a prospective database. Our 
prospective database was approved by the ethics committee of 
the Charité—Universitätsmedizin Berlin (Institutional Review 
Board number EA4/061/14). An ethics committee approval was 
not required for the current analysis, in accordance with laws and 
regulations in the Federal State of Berlin. Stroke severity on admis-
sion was assessed using the National Institutes of Health Stroke 
Scale (NIHSS) by a trained neurologist. Demographics, vascular 
risk factors (applying criteria used in prior research), admission 
blood pressure, glucose levels, creatinine, estimated glomerular 
filtration rate (eGFR), time from onset of stroke symptoms 
until treatment, previous medication including statin, and anti-
platelet use were recorded. Simvastatin 40  mg and simvastatin 
80 mg (or equivalents, see Table S1 in Supplementary Material) 
were defined as medium- and high-dose statin use, respectively 
(12, 15, 16). Renal impairment was assessed by eGFR using the 
CKD-EPI formula (13). Patients underwent neuroimaging before 
treatment and routinely 24–36 h after thrombolysis or earlier in 
case of deterioration. Brain images were analyzed by trained 
neuroradiologists. Presence of symptomatic hemorrhage accord-
ing to criteria of the European-Australasian Acute Stroke Study 
(ECASS-III) was recorded (17). The main outcome parameter 
was the occurrence of sICH after thrombolysis.
Data analysis, score Derivation, and 
score Validation
For categorical variables, proportions were calculated by dividing 
the number of events by the total number of patients, excluding 
missing or unknown cases. For continuous variables, median and 
interquartile ranges (IQR) were calculated.
We developed a score based on previous methodological 
recommendations (18). We performed a PubMed search to 
identify associated factors with sICH in patients treated with 
rt-PA. Based on reviews (19) and other published predictive 
scores for sICH (5–10), following factors were identified: older 
age, history of hypertension, ischemic heart disease, atrial 
fibrillation, congestive heart failure, diabetes, renal impair-
ment, treatment with antiplatelets prior to stroke, treatment 
with statins prior to stroke, severity of stroke measured by 
NIHSS, higher serum glucose levels, higher systolic blood 
pressure on admission, early signs of ischemic infarction on 
CT, leukoaraiosis, higher levels of triglycerides, higher weight, 
aPTT, prestroke mRS score, and longer time to treatment. Early 
CT signs of ischemic stroke, leukoaraiosis, triglycerides, aPTT, 
and prestroke mRS score were not registered in our database 
and therefore not considered in score derivation. The χ2 test was 
used for comparison of categorical variables. Comparisons of 
continuous variables were performed using the Mann–Whitney 
U-test. All factors with a P-value ≤0.10 were included in a mul-
tiple backward stepwise logistic regression analysis in order to 
identify characteristics that where associated with sICH. Based 
on the β-coefficients of the final multiple binary logistic regres-
sion model, we calculated the area under ROC (c-statistics) and 
95% CI of the score as a measure of discrimination of sICH. 
The resulting risk of sICH score (RICH score) was validated in 
an independent cohort of ischemic stroke patients treated with 
intravenous thrombolysis from the University Hospital Basel, 
Switzerland. Comparison with the previously published scores 
MSS (6) and THRIVE (7) were performed in the independent 
validation cohort. To facilitate the use of the score in the clinical 
setting, we additionally developed a final ordinal score based on 
the results of the multiple logistic regression analysis. For this, 
continuous variables were dichotomized and the optimal cutoff 
points were determined by choosing those cutoff points which 
yielded the highest odds ratios. Every item on the RICH score 
was assigned with 0 or 1 point. All tests were two-tailed and 
statistical significance was determined at an alpha level of 0.05. 
All statistical analyses were performed using SPSS (Version 
22.0) and STATA (Version 14.2).
resUlTs
Baseline characteristics
From 2006 to 2016, a total of 1,742 acute stroke patients were 
treated at the Charité (Berlin) stroke unit with rt-PA and included 
in our prospective database. Patients with a diagnosis of a stroke 
mimic at discharge (72; 4.1%), additional intraarterial throm-
bolysis and/or thrombectomy (228; 13.1%), and patients with 
unknown stroke onset and onset-to-treatment time >270  min 
(130; 7.5%) were not included in our analysis. A total of 1,336 
patients were eligible for analysis and score development (24 
patients with stroke of unknown onset underwent additional 
thrombectomy). Table 1 lists baseline characteristics of patients 
with and without sICH.
TaBle 3 | c­Statistics of the RICH, MSS, and THRIVE scores for risk of 
symptomatic intracranial hemorrhage (sICH) after systemic thrombolytic therapy 
for acute ischemic stroke in the validation cohort (Basel, n = 983).
score sich per ecass-iiia
RICH (n = 983) 0.69 (0.60–0.77)
MSS (n = 969) 0.66 (0.52–0.70)
THRIVE (n = 979) 0.67 (0.59–0.76)
ac-Statistics (95% CI).
TaBle 2 | Multiple regression analysis with β­coefficients for risk factors 
associated with symptomatic intracranial hemorrhage in the final model for the 
derivation group (n = 1,244), AUC: 0.72 (95% CI: 0.65–0.79).
item β-coefficient (95% ci) P-value
Age 0.034 (0.006–0.06) 0.02
National Institutes of Health Stroke Scale 
on admission
0.041 (0.001–0.08) 0.04
Glucose on admission 0.008 (0.003–0.01) 0.001
Systolic blood pressure on admission 0.01 (−0.0003 to 0.02) 0.057
Pretreatment with medium or high­dose 
statins
0.987 (0.32–1.66) 0.004
Constant term −9.134 (−11.96 to −6.31) <0.001
TaBle 1 | Demographics and baseline characteristics with univariate 
associations of patients with and without symptomatic intracranial hemorrhage 




Age, median [interquartile  
ranges (IQR)]
75 (67–83) 80 (72–87) 0.003
Sex, female (%) 623 (48.6) 27 (50.9) 0.73
Arterial hypertension (%) 1,066 (83.6) 46 (90.2) 0.21
Atrial fibrillation (%) 475 (37.4) 23 (45.1) 0.26
Diabetes mellitus (%) 309 (24.3) 18 (35.3) 0.07
Hyperlipidemia (%) 676 (53.6) 28 (56.0) 0.74
Previous stroke or transient  
ischemic attack (%)
339 (26.7) 14 (27.5) 0.90
Coronary artery disease (%) 260 (20.4) 13 (25.5) 0.38
Antiplatelets (%) 523 (42.7) 29 (58.0) 0.03
Statins (%)a 165 (12.9) 13 (24.5) 0.01
National Institutes of Health Stroke 
Scale (NIHSS), median (IQR)
8 (4–15) 10 (7–19) 0.008
NIHSS ≥5 (%) 830 (64.7) 44 (83.0) 0.06
Onset­to­treatment time (min),  
median (IQR)
112 (85–151) 126 (92–155) 0.31
Systolic blood pressure (mmHg), 
median (IQR)
152 (136–172) 160 (148–181) 0.04
Glucose (mg/dL), median (IQR) 121 (107–148) 138 (119–171) 0.001
Estimated glomerular filtration rate 
(eGFR), median (IQR)
66 (49–81) 62 (47–81) 0.29
Severe renal impairment  
(eGFR ≤ 30) (%)
64 (5.0) 5 (9.4) 0.15
aNo or low-dose statins vs. medium or high-dose statins.
TaBle 4 | Multiple logistic regression analysis with odds ratios for dichotomized 
risk factors associated with symptomatic intracranial hemorrhage in the final 
model and assigned points for each variable.
item Or (95% ci) P-value Points
Age >80 years 1.8 (1.03–3.3) 0.04 1
National Institutes of Health Stroke Scale 
≥5
2.4 (1.1–5.0) 0.02 1
Glucose >125 mg/dL 2.5 (1.4–4.5) 0.003 1
Systolic blood pressure >155 mmHg 2.0 (1.1–3.3) 0.02 1
Pretreatment with medium or high­dose 
statinsa
2.6 (1.3–5.1) 0.005 1
aMedium or high-dose statins: atorvastatin (10, 20, 40, and 80 mg), rosuvastatin (5, 10, 
and 20 mg), simvastatin (40 and 80 mg) (see Table S1 in Supplementary Material for a 
complete list of statins).
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risk Factors of intracranial hemorrhage 
and score Development
Symptomatic ICH according to ECASS-III-criteria occurred in 
53 patients (4.0%). In multiple logistic regression analysis, older 
age, higher stroke severity measured by NIHSS upon admis-
sion, higher blood glucose upon admission, and treatment with 
medium or high-dose statins before the acute event were associ-
ated with sICH (Table 2). Systolic blood pressure upon admission 
was added into the model according to the literature. Table 2 lists 
all items of the resulting RICH score. The c-statistics of the RICH 
score for discrimination of sICH was 0.72 (95% CI 0.66–0.79) in 
the derivation cohort.
Validation and comparison of scores
The score was then validated and compared with other scores in 
the thrombolysis registry of the University Hospital Basel, which 
included 983 patients of whom 33 (3.4%) had a sICH. Table 3 
shows the c-statistics for the RICH score and other scores in the 
validation cohort. The RICH score discriminated sICH in the 
validation cohort with a c-statistic of 0.69 (95% CI 0.60–0.77). 
There was no significant difference regarding discriminatory abil-
ity compared to the MSS and THRIVE scores. We also assessed 
the ability to discriminate sICH using alternative models with 
different combinations of additional variables including severe 
renal impairment. None resulted in significant changes of the 
discriminative ability of the score.
For ease of use of the RICH score, we developed a risk cal-
culator giving the probability of sICH after thrombolysis based 
on individual patient data (see Data Sheet S1 in Supplementary 
Material). In addition, we developed a final ordinal score based 
on the results of the multiple logistic regression analysis to further 
facilitate the use of the score in the clinical setting. For this, we 
dichotomized continuous variables and assigned one point for 
each risk factor (Table 4). Figure 1 shows the frequency of sICH 
according to points on the RICH score.
DiscUssiOn
The RICH score is an easy and quick computable score for the risk 
of sICH in patients with an acute stroke treated with intravenous 
rt-PA. Its simplicity and fair discriminatory ability may help clini-
cians to identify patients with higher or low risk of sICH after 
rt-PA. All items of the score are easy and quick to obtain and do 
not require interpretation. While incorporating well-known risk 
factors of sICH such as age, stroke severity, and admission levels 
of blood glucose, our score differs from other published scores 
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in considering pretreatment with medium or high-dose statins 
as additional risk factor. Furthermore, in contrast to many other 
scores, the RICH score does not include early signs of ischemic 
infarction on CT, which may facilitate its use.
Several scores for the risk of sICH after rt-PA have been pub-
lished in recent years (5–10). Most involve established risk factors 
of sICH such as age (MSS, SEDAN, SITS-sICH, and THRIVE), 
stroke severity (MSS, HAT, SEDAN, SITS-sICH, and THRIVE), 
level of blood glucose on admission (MSS, HAT, SEDAN, and 
SITS-sICH), and early signs of ischemic infarction on CT (HAT 
and SEDAN). The accuracy of these previously published scores 
is therefore overall comparable. In studies comparing scores 
for sICH, the c-statistic ranged mostly between 0.60 and 0.80, 
suggesting the accuracy was modest to good (20, 21). Therefore, 
identifying additional risk factors of sICH may improve the 
accuracy of predictive scores, making them more precise (22, 
23). Our study shows that preexisting treatment with medium 
and high-dose statins is possibly an important additional risk 
factor and should be considered in future studies investigating 
rt-PA-related hemorrhage. Inclusion of severe renal impairment 
on the other hand did not improve the discriminatory ability of 
the score. This may be attributable to a small effect size of renal 
impairment on sICH, which may have precluded detection of an 
effect in the current cohorts due to the relatively low number of 
patients with sICH.
Risk factors for sICH after thrombolysis such as stroke 
severity, onset-to-treatment time, and early signs of infarction 
on CT may reflect the extent and progression of ischemic injury 
to the blood–brain barrier. Other risk factors such as stroke-
associated hyperglycemia and hypertension may represent an 
acute stroke-related stress reaction (24, 25), and there is debate 
whether stroke-associated hyperglycemia is merely an epiphe-
nomenon (and a marker) or a cause of poor outcome and sICH 
(22, 26). In contrast to these risk factors, the novel candidate 
risk factor pretreatment with statins may contribute to a higher 
risk of clinically relevant hemorrhage after rt-PA via different 
mechanisms. More specifically, a higher dose-dependent risk 
of cerebral hemorrhage after thrombolytic therapy may be 
attributable to antithrombotic and anticoagulative properties 
of statins (27, 28).
It is important to note that a higher risk of sICH on a score alone 
does not justify withholding treatment with rt-PA (29). Whiteley 
et al. have shown that patients with higher predicted risk of sICH 
still had a clinically relevant positive effect from therapy with 
rt-PA (11). Instead, the RICH score may be an additional tool to 
(a) identify patients who may benefit from intensified monitoring 
of putative complications and (b) to identify patients with a very 
low risk of sICH (provided that there are no contraindications 
for rt-PA). The RICH score may possibly represent an alternative 
to established scores in clinical settings where a fast and reliable 
assessment of early ischemic changes on CT is not available. All 
the items of the RICH score are part of the routine check-up for 
stroke patients that are suitable for rt-PA, and therefore easily 
available and quick to perform. Comparison with existing scores 
(namely MSS and THRIVE) proved a fair discriminatory ability 
of the RICH score.
Although we derived our score using data from a large single-
center cohort and sICH rates were similar to previous studies (1, 
2, 30), the number of patients with sICH was small. This may have 
led to over fitting and thus over-optimism regarding the goodness 
of fit of our final model in our derivation cohort. However, valida-
tion of the RICH score in an independent stroke cohort showed 
a significant predictive value.
cOnclUsiOn
The RICH score may help clinicians to identify patients with low 
and higher risk of rt-PA related sICH. Inclusion of novel candidate 
risk factors for sICH such as pretreatment with medium or high-
dose statins may improve the accuracy of predictive instruments. 
FigUre 1 | Frequency of symptomatic intracranial hemorrhage (sICH) according to points on the RICH score. Patients at risk: 0 points = 6.7%, 1 point = 25.0%, 2 
points = 33.3%, 3 points = 25.9%, ≥4 points = 9.0%.
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However, a higher risk of sICH on the RICH score alone should 
not preclude patients from thrombolysis.
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